RxDoctor Payments Data

Donna McHugh, MD

Internal Medicine · Winsted, CTNPI 1518949536

Payments from drug & device makers

$810in general payments, 2019–2025

Across 42 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$424
  • GSK$125
  • Kowa Pharmaceuticals America, Inc.$48
  • AstraZeneca$47
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$46
  • Amgen$37
  • plus $83 from 4 others

What the payments were for

  • Food & beverage$810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$810 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$19,712
Medicare patients
61
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$65,790
ProliaDenosumab21$36,034
JanuviaSitagliptin Phosphate11$23,007
Breo ElliptaFluticasone/Vilanterol14$5,536
Wixela InhubFluticasone Propion/Salmeterol25$2,553
Levothyroxine Sodium214$2,127
Zafirlukast12$2,074
SynthroidLevothyroxine Sodium26$1,879
Omeprazole98$1,709
Atorvastatin Calcium139$1,443
Levemir FlexpenInsulin Detemir14$1,371
Rosuvastatin Calcium118$1,065
Amlodipine Besylate147$929
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$900
Alprazolam106$848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$65,79063 claims
AmgenProlia$37$36,03421 claims
GSKBreo Ellipta$125$5,53614 claims
AbbVieSynthroid$424$1,87926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Winsted

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →